BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

Here’s what you need to know about BioAge’s IPO. BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm based in ...

More on BioAge Labs, Inc. BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment Weight-loss drug developer BioAge ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

BioAge CEO and co-founder Kristen Fortney would own 6.7% of the company after the IPO. The offering would be the first Bay Area biotech IPO since February and only the fourth this year.

"The third quarter of 2024 was transformative for BioAge as we achieved two major milestones: initiating our Phase 2 STRIDES trial evaluating azelaprag in combination with tirzepatide, and completing ...

At the closing bell, BioAge’s stock BIOA stood at $18.31 for a 1.7% gain over its IPO price. Earlier, the stock had been up as much as 30%.

In that vein, there's a biotech stock called BioAge Labs (NASDAQ: BIOA) that just wrapped up its initial public offering (IPO) and is aiming to compete in the same areas as Lilly, as well as one ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...